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Background. Women with polycystic ovary syndrome (PCOS) could develop subclinical atherosclerosis during life. Purpose. To
analyze cardiovascular risk (CVR) factors and their relation to clinical markers of cardiovascular disease (CVD) in respect to their
age. Material and Methods. One hundred women with PCOS (26.32 ± 5.26 years, BMI: 24.98 ± 6.38 kg/m2) were compared to 50
respective controls. In all subjects, total cholesterol (TC), HDL-C, LDL-C, triglycerides, TC/HDL-C andTG/HDL-C ratios, glucose,
insulin andHOMA index, waist-to-hip ratio (WHR), systolic and diastolic blood pressure (SBP andDBP, resp.), and carotid intima-
media thickness (CIMT) were analyzed in respect to their age and level of androgens. Results. PCOS over 30 years had higherWHR
(𝑃 = 0.008), SBP (𝑃 < 0.001), DBP (𝑃 < 0.001), TC (𝑃 = 0.028), HDL-C (𝑃 = 0.028), LDL-C (𝑃 = 0.045), triglycerides (𝑃 < 0.001),
TC/HDL-C (𝑃 < 0.001), and triglycerides/HDL-C (𝑃 < 0.001) and had more prevalent hypertension and pronounced CIMT on
common carotid arteries even after adjustment for BMI (𝑃 = 0.005 and 0.036, resp.). TC/HDL-C and TG/HDL-C were higher
in PCOS with the highest quintile of FAI in comparison to those with lower FAI (𝑃 = 0.045 and 0.034, resp.). Conclusions. PCOS
women older than 30 years irrespective of BMI have the potential for early atherosclerosismirrored through the elevated lipids/lipid
ratios and through changes in blood pressure.
1. Introduction
Polycystic ovary syndrome (PCOS) is the most common
endocrine disorder in premenopausal women, with a preva-
lence of 6–10%, and it is characterized by hyperandrogenic
features and chronic oligoanovulation [1, 2]. In addition to
obesity, insulin resistance and an impaired 𝛽 cell function
of the pancreas, dyslipidemia, and hypertension are more
prevalent compared to the general population. An altered
lipid profile in PCOS women is characterized by elevated
triglycerides, normal or increased concentrations of total and
LDL cholesterol, decreased HDL cholesterol, and an increase
in specific lipid ratios [3, 4].
Several studies have shown that women with PCOS
have an increased prevalence of hypertension. While some
authors showed that a higher prevalence of hypertension was
related to the obesity and not to PCOS per se [5], others
demonstrated that a high value of the free androgen index
(FAI) in even young women with PCOS was associated with
hypertension independent of insulin resistance, body mass
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index (BMI), and dyslipidemia [6]. Controversy over the
cardiovascular disease (CVD) and outcomes in women with
PCOS continues towards menopause. Shaw et al. have shown
that menopausal women with PCOS characteristics more
frequently had diabetes, obesity, metabolic syndrome (MetS),
and signs of coronary heart disease (CHD) [7]. However,
other authors did not find an association between PCOS
and CHD or increased rates of cardiovascular morbidity and
mortality [8].
Endothelial dysfunction is one of the earliest signs of
subclinical atherosclerosis. If we consider that women with
PCOS are exposed to risk factors for CVD early in life, the
diagnosis of subclinical atherosclerosis in this population
would be of importance. Ultrasonographic measurement
of the carotid intima-media thickness (CIMT) is a reliable
and noninvasive method for the determining of preclini-
cal atherosclerosis. Increased CIMT is correlated with an
increased risk of cardiovascular events such as myocardial
infarction and stroke in the general population [9].
Taking into consideration the probability of the existence
of preclinical CVD in women with PCOS, the aim of this
study was to analyse the relation between lipid disarrange-
ment, as the most frequent metabolic abnormality in PCOS,
and markers of CVD, primarily arterial blood pressure, in
respect to their age and androgen levels.
2. Materials and Methods
2.1. Selection of the Subjects. The study included 100 women
with a confirmed diagnosis of PCOS (mean age 26.32 ±
5.26 years and BMI 24.98 ± 6.38 kg/m2) and 50 healthy
controls (mean age 27.96 ± 5.66 years and BMI 24.66 ±
6.74 kg/m2). Subjects included in the study were referred
to the outpatient endocrinology clinic, because of irregular
menstrual cycles, hirsutism, or acne. PCOS was defined on
the basis of the revised Rotterdam consensus in 2003 [10]
which implies the presence of at least two of the following
three criteria: moderate oligo/amenorrhea (fewer than eight
menstrual cycles in a year), presence of clinical hyperandro-
genism (hirsutism) and/or biochemical hyperandrogenemia
[11], and ultrasound confirmation of the existence of poly-
cystic ovaries. Hirsutism was defined as Ferriman-Gallwey
score ≥8 [12]. Biochemical hyperandrogenemia was defined
as total testosterone>2.0 nmol/L and/or FAI≥6.Womenwith
PCOS were analyzed during the early follicular phase of the
regular menstrual cycle, or at any time if they had severe
oligomenorrhea or were amenorrheic.
A control group of healthy women had no signs of
hyperandrogenism. Normal ovulatory status in controls was
confirmed by the measurement of serum progesterone levels
during the luteal phase of the menstrual cycle. Progesterone
>10 nmol/L was considered ovulatory. Normal appearance
of the ovaries was confirmed by ultrasound examination.
Woman with the presence of elevated fasting glucose (fasting
venous glucose ≥6mmol/L), pregnancy, history of alcohol
or drug abuse, and medical history of breast cancer and
uterine and cardiovascular disorders were excluded from
the study. Also, hypothyroidism, nonclassical form of 21-
hydroxylase deficit, hyperprolactinemia, Cushing’s disease,
and androgen-secreting tumorswere excluded by appropriate
tests. None of the subjects received oral contraceptives, gluco-
corticoids, antiandrogens, and other hormonal agents known
to affect menstrual cyclicity or the drugs for the treatment
of diabetes and obesity, for at least three months before the
commencement of the study.
The study was approved by the Institutional Ethics Com-
mittee and all examined women gave written informed
consent before the study.
2.2. Anthropometric and Biochemical Characteristics of the
Subjects. In all subjects, BMI, waist-to-hip ratio (WHR), and
systolic and diastolic arterial blood pressure (SBP and DBP,
resp.) were determined. BMI (kg/m2) was calculated as the
ratio of body weight (kg) and body height (m) squared.
WHR was calculated as the ratio of the smallest waist
circumference (cm) at the level of umbilicus to maximal
hip circumference (cm). SBP (mmHg) and DBP (mmHg)
were measured using mercury sphygmomanometer on the
left arm in a sitting position by the same examiner. The
average of two measurements was calculated. According to
the criteria used in all definitions for metabolic syndrome
[13], hypertension was defined as SBP ≥130mmHg and/or
DBP ≥85mmHg. Determination of CIMT was performed
by ultrasound, using linear probe (7.5–10MHz) as previously
described [14]. Measurement was performed on both com-
mon (ACC) and internal carotid arteries (ACI), and mean
values of CIMT on ACC and ACI were determined.
Baseline blood samples were collected after 12 hours of
fasting in the follicular phase of the cycle (between the 3rd
and the 7th days) or randomly in a case of amenorrhea,
and the following analyses were determined: total cholesterol
(TC), HDL-cholesterol (HDL-C), LDL-cholesterol (LDL-C),
triglycerides (TG), apolipoprotein A1 (Apo-A1), apolipopro-
tein B (Apo-B), glucose, insulin, total testosterone, sex-
hormone-binding globulin (SHBG), androstenedione, and
dehydroepiandrosterone sulfate (DHEAS). The samples for
hormone analysis were stored on −80∘C until measurement.
TC (mmol/L) and TG (mmol/L) were measured by stan-
dard enzymatic methods (TC: cholesterol oxidase, Randox,
Belfast, UK; TG: glycerol-3-phosphate oxidase, Randox, UK).
HDL-C (mmol/L) was measured by the direct method (Ran-
dox, UK). LDL-C l (mmol/L) was determined by Friedewald
formula. Apo-A1 (g/L) and Apo-B (g/L) were determined
by nephelometric method (Behring, Marburg, Germany).
Blood glucose (mmol/L) was measured by glucose oxidase
method (Randox, UK), using the autoanalyzer (Beckman,
Austria), and plasma insulin (mU/L) was measured using
radioimmunoassay RIA INSULIN (PEG, INEP, Belgrade,
Serbia). Serum total testosterone (nmol/L), androstenedione
(ng/mL), DHEAS (nmol/L), and SHBG (nmol/L) were
measured by radioimmunoassay (Testo-CT2, R-GM-100,
DHEAS-CT, and SHBG-RIACT, resp.; CIS Bio International,
Gifsur-Yvette, France). FAI was calculated by the formula
[(100× total testosterone)/SHBG]. Insulin resistance (IR) was
determined using HOMA (homeostasis model assessment)
International Journal of Endocrinology 3
index, which is calculated by the formula: [fasting insulin
(mU/L) × fasting glucose (mmol/L)]/22.5. TC/HDL-C <4
[15, 16] and TG/HDL-C <2 [17] were considered desirable.
In order to evaluate the age dependency, both PCOS and
controls were divided into two subgroups: younger and older
than 30 years. Additionally, in order to evaluate the influence
of hyperandrogenism, PCOS group was also divided into two
subgroups according to FAI quintiles.
2.3. Statistical Analysis. Statistical analysis was performed
using the Statistical Package for Social Science (version 13.0,
SPSS Inc., Chicago, IL). The level of significance was set
on 0.05. For comparison between groups, Student’s 𝑡-test
for two independent samples for parametric data and 𝜒2
test for nonparametric data and binomial variables were
used. Results are presented as mean ± standard deviation
(𝑥 ± SD) for continuous variables and as percentages for
binary variables. Associations between different variables
were determined using Spearman correlation coefficient with
two-tailed test of significance. In order to analyze potential
predictors of SBP and DBP, univariant linear regression anal-
ysis was performed with parameters that significantly cor-
related with SBP and DBP. All significant predictors form
univariant regression analysis entered stepwise multiple lin-
ear regression analysis. In order to get the cut-off values of
independent predictors for hypertension, we generated the
receiver operating characteristic (ROC) curves separately in
subgroups PCOS <30 years and PCOS ≥30 years. The areas
under the curve (AUCs) are provided with standard error
of mean (SEM) and 95% confidence intervals (95% CI). The
ROC curves, a plot of the sensitivity (SEN) (true positive)
versus 1-specificity (SP) (false positive) for each predictor
tested, determine the ability of a screening measure for
correctly identifying individuals based on their classification
by a reference test. The values for each AUC can be between
0 and 1, with a value of 0.5, indicating that the diagnostic test
is no better than chance. We considered that parameter has
an accurate diagnostic sensitivity whenAUC value was>0.75.
We defined the best cut-off value as the value with the highest
proportion of positives and negatives classified correctly by
the test.
3. Results
3.1. Clinical Characteristics of Women with PCOS and Con-
trols. Clinical characteristics and respective biochemical
analyses for the whole group of PCOS women and controls
are presented in Table 1. Groups were comparable by age
and BMI, but PCOS had higher degree of centripetal obesity
(WHR, 𝑃 = 0.03). SBP and DBP, lipid parameters, fasting
glucose, insulin, and HOMA index did not differ between
groups. As expected, women with PCOS had significantly
higher levels of testosterone and FAI.
There were no differences between PCOS and controls
in the prevalence of hypertension (30% versus 20%, 𝑃 =
0.192), increased TC/HDL-C ratio (≥4) (38% versus 28%,
𝑃 = 0.225), or TG/HDL-C (9% versus 8%, 𝑃 = 0.552). There
was no significant difference in CIMT between PCOS and
Table 1: Clinical and biochemical parameters in women with PCOS
and controls.
Parameter PCOS(𝑛 = 100)
Controls
(𝑛 = 50) 𝑃 value
Age (years) 26.32 ± 5.26 27.96 ± 5.66 0.082
BMI (kg/m2) 24.98 ± 6.38 24.66 ± 6.7 0.781
WHR 0.84 ± 0.11 0.80 ± 0.07 0.033
SBP (mmHg) 119.53 ± 11.28 117.60 ± 11.83 0.333
DBP (mmHg) 77.39 ± 9.47 75.90 ± 9.35 0.362
TC (mmol/L) 5.07 ± 1.01 4.98 ± 1.04 0.619
HDL-C (mmol/L) 1.36 ± 0.33 1.37 ± 0.29 0.857
LDL-C (mmol/L) 3.16 ± 0.87 3.12 ± 0.93 0.782
TG (mmol/L) 1.20 ± 0.74 1.07 ± 0.71 0.305
Glucose (mmol/L) 4.69 ± 0.51 4.61 ± 0.42 0.329
Insulin (mU/L) 16.35 ± 9.62 16.18 ± 9.04 0.920
HOMA 3.46 ± 2.28 3.30 ± 1.85 0.678
Apo-A1 (g/L) 1.59 ± 0.31 1.63 ± 0.32 0.434
Apo-B (g/L) 0.91 ± 0.29 0.87 ± 0.26 0.400
TC/HDL-C 3.90 ± 1.15 3.78 ± 1.21 0.542
TG/HDL-C 1.0 ± 0.79 0.87 ± 0.75 0.354
Testosterone (nmol/L) 2.66 ± 0.99 1.64 ± 0.60 <0.001
SHBG (nmol/L) 38.67 ± 23.18 55.66 ± 32.0 <0.001
FAI 10.15 ± 10.22 4.1 ± 2.8 <0.001
Androstenedione (ng/mL) 3.39 ± 1.36 2.14 ± 1.11 <0.001
DHEAS (nmol/L) 8.15 ± 4.01 5.33 ± 2.92 <0.001
BMI: body mass index; WHR: waist-to-hip ratio; SBP: systolic blood
pressure; DBP: diastolic blood pressure; TC: total cholesterol; HDL-C:
high-density lipoprotein; LDL-C: low-density lipoprotein; TG: triglycerides;
HOMA: homeostatic model assessment; Apo-A1: apolipoprotein A1; Apo-
B: apolipoprotein B; DHEAS: dehydroepiandrosterone sulfate; SHBG: sex-
hormone-binding globulin; FAI: free androgen index.
controls on either ACC (0.54 ± 0.63 versus 0.47 ± 0.07, resp.)
or ACI (0.53 ± 0.63 versus 0.47 ± 0.07, resp.).
3.2. Effect of Aging on Lipid Parameters. For the more accu-
rate analyses of the cardiovascular risk (CVR) factors related
to age, all subjects were divided using age cut-off of 30
years and the differences are presented in Table 2. Except the
expected difference in levels of androgens, PCOS and controls
younger than 30 years did not differ in any other metabolic
or cardiovascular indices. PCOS older than 30 years had
higher BMI, WHR, SBP, DBP, all lipids and their ratios,
and Apo-B than PCOS younger than 30 years. Significant
difference remained for SBP, DBP, TG, insulin, and FAI after
the adjustment for BMI. PCOS older than 30 years had higher
WHR, SBP, DBP, TG, and TG/HDL-C than respective control
subgroup.
Prevalence of hypertension was not different between
PCOS and controls younger than 30 years (20% versus 22%,
𝑃 = 0.801) while, in the older subgroups, PCOS had sig-
nificantly higher prevalence of hypertension than controls
(61% versus 17%,𝑃 = 0.003). In comparison to PCOS younger
than 30 years, prevalence of hypertensionwas higher in PCOS
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in the fourth decade (𝑃 < 0.001), even after adjustment for
BMI (𝑃 = 0.005).
Prevalence of TC/HDL-C ≥4 did not differ between
PCOS and controls younger than 30 years (27% versus 25%,
𝑃 = 0.807) while in the older subgroups it wasmore prevalent
in PCOS in comparison to controls (71% versus 33%, 𝑃 =
0.016). Prevalence of TC/HDL-C ≥4 was higher in PCOS in
the fourth decade in comparison to those younger than 30
years (𝑃 < 0.001), even after adjustment for BMI (𝑃 = 0.025).
There was no difference in the prevalence of TG/HDL-C ≥2
between PCOS and controls younger than 30 years (𝑃 =
0.402) and older than 30 years (𝑃 = 0.214). In comparison to
PCOS younger than 30 years, prevalence of TG/HDL-C ≥2
was higher in PCOS in the fourth decade (20% versus 5%,
𝑃 = 0.034) but remained insignificant after adjustment for
BMI (𝑃 = 0.693).
PCOS and controls younger than 30 years and older than
30 years had similar CIMT on ACC (𝑃 = 0.197 and 0.142,
resp.) and ACI (𝑃 = 0.201 and 0.103, resp.). PCOS ≥30
years had higher CIMT on ACC in comparison to PCOS
<30 years (0.47 ± 0.08 versus 0.44 ± 0.06, 𝑃 = 0.043), even
after adjustment for BMI (𝑃 = 0.036), while there was no
difference on ACI (𝑃 = 0.299). Controls ≥30 years had
higher CIMT on ACC in comparison to controls <30 years
(0.50±0.06 versus 0.46±0.05, 𝑃 = 0.009), while there was no
difference on ACI (𝑃 = 0.060).
3.3. Clinical and Biochemical Characteristics Related to the
Level of FAI. For the assessment of possible influence of
androgens on cardiovascular risk factors and outcomes,
PCOS group was analyzed related to the quintiles of FAI.
Subgroupwith the highest quintile of FAI (≥11) was compared
to the joint subgroup consisting of subjects with FAI <11.
The PCOS subgroups did not differ in age, but women with
the highest FAI quintile were more obese in comparison to
the women with lower FAI (29.04 ± 7.04 versus 23.36 ±
5.34 kg/m2, 𝑃 < 0.001). Although PCOS subgroup with
the highest FAI quintile in comparison to the joint PCOS
subgroup with lower FAI had higher SBP, DBP, TG, and lipid
ratios, the only significant differences that remained after
adjustment for BMIwere for the ratios of TC/HDL (4.58±1.28
versus 3.46 ± 0.99, 𝑃 = 0.045) and TG/HDL (1.47 ± 0.93
versus 0.81±0.65,𝑃 = 0.034). Prevalence of hypertensionwas
not different among the subgroups of FAI (39% versus 27%,
𝑃 = 0.230).There were no differences in CIMT related to FAI
subgroups on either ACC or ACI, even after BMI adjustment
(𝑃 = 0.076 and 𝑃 = 0.100, resp.).
3.4. Correlations of Clinical and Biochemical Parameters. In
PCOS subjects, SBP significantly correlated with age (rho =
0.317, 𝑃 < 0.001), BMI (rho = 0.375, 𝑃 < 0.001), WHR
(rho = 0.322, 𝑃 < 0.001), TG (rho = 0.236, 𝑃 = 0.011),
TG/HDL-C (rho = 0.236, 𝑃 = 0.010), TC/HDL-C (rho =
0.265, 𝑃 = 0.004), and Apo-B (rho = 0.302, 𝑃 < 0.001). DBP
significantly correlated with age (rho = 0.362, 𝑃 < 0.001),
BMI (rho = 0.383,𝑃 < 0.001),WHR (rho = 0.336,𝑃 < 0.001),
TG (rho = 0.284, 𝑃 = 0.002), TG/HDL-C (rho = 0.298,
𝑃 = 0.001), TC/HDL-C (rho = 0.309, 𝑃 = 0.001), Apo-A1
(rho = −0.227, 𝑃 < 0.017), Apo-B (rho = 0.328, 𝑃 < 0.001),
and FAI (rho = 0.215, 𝑃 = 0.021). TC/HDL-C significantly
correlated with WHR (rho = 0.549, 𝑃 < 0.001), BMI (rho =
0.552, 𝑃 < 0.001), HOMA (rho = 0.193, 𝑃 = 0.040), and FAI
(rho = 0.369, 𝑃 < 0.001). TG/HDL-C significantly correlated
with WHR (rho = 0.524, 𝑃 < 0.001), BMI (rho = 0.569,
𝑃 < 0.001), HOMA (rho = 0.311, 𝑃 = 0.001), and FAI (rho =
0.432, 𝑃 < 0.001). CIMT did not correlate with either lipid
parameters or their specific indices in PCOS group.
In control subjects, SBP significantly correlated with total
testosterone (rho = 0.359, 𝑃 = 0.010), DHEAS (rho = 0.288,
𝑃 = 0.045), and androstenedione (rho = 0.435, 𝑃 = 0.003),
while DBP significantly correlated with WHR (rho = 0.331,
𝑃 = 0.019), total testosterone (rho = 0.338, 𝑃 = 0.016), FAI
(0.346, 𝑃 = 0.021), and androstenedione (rho = 0.435, 𝑃 =
0.003). TC/HDL-C significantly correlated withWHR (rho =
0.418, 𝑃 < 0.001), BMI (rho = 0.555, 𝑃 < 0.001), HOMA (rho
= 0.424, 𝑃 = 0.001), and FAI (rho = 0.519, 𝑃 < 0.001), while
TG/HDL-C correlated with WHR (rho = 0.329, 𝑃 = 0.020),
BMI (rho = 0.492, 𝑃 < 0.001), and FAI (rho = 0.518, 𝑃 <
0.001).
In the subgroup of PCOS <30 years, SBP and DBP
significantly correlated with BMI (rho = 0.265, 𝑃 = 0.013
and rho = 0.309, 𝑃 = 0.003, resp.) and DHEAS (rho = 0.263,
𝑃 = 0.014 and rho = 0.266, 𝑃 = 0.013, resp.). WHR sig-
nificantly correlated with TC (rho = 0.329, 𝑃 = 0.02), HDL
(rho = −0.271, 𝑃 = 0.011), LDL (rho = 0.357, 𝑃 = 0.001), TG
(rho = 0.416, 𝑃 < 0.001), TC/HDL (rho = 0.451, 𝑃 < 0.001),
TG/HDL (rho = 0.398, 𝑃 < 0.001), Apo-B (rho = 0.439,
𝑃 < 0.001), insulin (rho = 0.399, 𝑃 < 0.001), HOMA (rho =
0.398, 𝑃 < 0.001), and SHBG (rho = −0.330, 𝑃 = 0.002). In
PCOS ≥30 years SBP and DBP significantly correlated with
WHR (rho = 0.621, 𝑃 < 0.001 and rho = 0.472, 𝑃 = 0.011,
resp.), TG (rho = 0.467,𝑃 = 0.012 and rho = 0.595,𝑃 = 0.001,
resp.), Apo-B (rho = 0.473, 𝑃 = 0.015 and rho = 0.393,
𝑃 = 0.047, resp.), andTG/HDL-C (rho= 0.473,𝑃 = 0.011 and
rho = 0.589, 𝑃 = 0.001, resp.). Besides the above mentioned
correlations with SBP andDBP,WHR significantly correlated
also with TG (rho = 0.521, 𝑃 = 0.004), TG/HDL (rho = 0.545,
𝑃 = 0.003), Apo-B (rho = 0.438, 𝑃 = 0.025), insulin (rho =
0.510, 𝑃 = 0.006), HOMA (rho = 0.502, 𝑃 = 0.008), and
SHBG (rho = −0.532, 𝑃 = 0.004).
In PCOS with the highest FAI, TG/HDL-C significantly
correlated with WHR (rho = 0.471, 𝑃 = 0.006) and BMI
(rho = 0.585, 𝑃 < 0.001). SBP and DBP significantly cor-
related with WHR (rho = 0.396, 𝑃 = 0.023 and rho = 0.384,
𝑃 = 0.027, resp.) and BMI (rho = 0.506, 𝑃 = 0.003 and rho =
0.423,𝑃 = 0.014, resp.). In PCOSwith lower FAI, TG/HDL-C
significantly correlated with WHR (rho = 0.417, 𝑃 < 0.001)
and BMI (rho = 0.409, 𝑃 < 0.001). SBP and DBP significantly
correlated with WHR (rho = 0.255, 𝑃 = 0.020 and rho =
0.264, 𝑃 = 0.016, resp.) and BMI (rho = 0.262, 𝑃 = 0.017
and rho = 0.320, 𝑃 = 0.003, resp.).
3.5. Linear Regression Analysis. In order to determine signif-
icant predictors for SBP and DBP in the PCOS group, we
performed uni- and multivariate linear regression analyses
with SBP and DBP as dependent variables, separately in
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Table 3: Independent predictors of systolic and diastolic blood pressure in PCOS related to age.
Predictors Unstandardized coefficients 𝐵 95% confidence interval for 𝐵 𝑃 value
Lower Upper
PCOS <30 years
SBP (𝑅2 = 0.16)
BMI 0.532 0.126 0.938 0.011
DHEAS 0.577 0.094 1.060 0.020
DBP (𝑅2 = 0.13)
BMI 0.431 0.069 0.793 0.020
DHEAS 0.465 0.034 0.896 0.035
PCOS ≥30 years
SBP (𝑅2 = 0.42)
TG/HDL-C 4.908 0.307 9.509 0.038
WHR 57.050 2.058 112.043 0.043
DBP (𝑅2 = 0.47)
TG/HDL-C 5.708 2.363 9.053 0.002
SBP: systolic blood pressure; BMI: body mass index; DHEAS: dehydroepiandrosterone sulfate; DBP: diastolic blood pressure; TG: triglycerides; HDL-C: high-
density lipoprotein; WHR: waist-to-hip ratio.
PCOS <30 years and PCOS ≥30 years. Independent vari-
ables included in analyses were only those that significantly
correlated with SBP and DBP in both PCOS subgroups.
Accordingly, dependent predictors for SBP and DBP in
PCOS <30 years were BMI and DHEAS, and both of those
remained significant predictors of SBP in multiple regression
analysis (Table 3). In PCOS ≥30 years dependent variables
for both SBP and DBP were WHR, Apo-B, and TG/HDL-C.
In multiple linear regression analysis, significant predictors
of SBP remained TG/HDL-C and WHR, while the only
significant predictor for DBP was TG/HDL-C (Table 3).
3.6. ROCCurve Analysis. Wehave performed the ROC curve
analysis for various predictors of hypertension in PCOS
group.
In subgroup PCOS <30 years, BMI and DHEAS were
considered. However, the resulting values BMI [AUC: 0.676±
0.065 (0.549–0.803), 𝑃 = 0.022] and DHEAS [AUC: 0.636 ±
0.083 (0.474–0.798), 𝑃 = 0.077] appeared to be insignificant
according to our presumptions (see methodology), so the
cut-off values for those indices could not be formed.
In subgroup PCOS ≥30 years, TG/HDL-C exhibited high
diagnostic accuracy for prediction of hypertension [AUC:
0.81 ± 0.083 (0.644–0.971), 𝑃 = 0.007]. Cut-off value 1.10
had SEN: 82.4% and SP: 72.7% for prediction of hypertension
in PCOS ≥30 years. The obtained cut-off value had higher
positive predictive value (PPV 82%) than negative predictive
value (NPV 73%) (𝑃 = 0.006). Yet, in the general PCOS
population, this cut-off value produced higher negative (NPV
76%) than positive predictive value (PPV 51%) (𝑃 = 0.004).
4. Discussion
In this study, we obtained significantly higher values of
SBP and DBP as well as the prevalence of hypertension
in our population of PCOS women over 30 years of age
in comparison to younger PCOS women and respective
controls. The same type of the age-related change towards
higher values in PCOS women over 30 years was obtained
for triglycerides. Moreover, women with PCOS and the most
pronounced hyperandrogenemia,mirrored through FAI, had
significantly higher proatherogenic lipid indexes as TG/HDL
and TC/HDL, thus implicating the role of androgens in such
metabolic derangements.These results were maintained after
adjustment for the BMI of the investigated PCOS women.
According to the literature data, this is the first study to show
an aggravation of arterial blood pressure and lipid indices in
the PCOS age group over 30 years after adjustment for BMI
as the most disputable confounding factor in related studies.
The assessment of arterial blood pressure represents a
valuable clinical surrogate maker for coexisting CVD. The
prevalence of hypertension varies in the studied PCOS
populations and their clinical phenotypes [18, 19]. One expla-
nation could be the impact of ethnicity. However, it is still
unclear whether PCOS women have a higher prevalence of
hypertension in comparison to reproductive healthy women
or not, because it is not usually controlled for obesity in the
majority of studies [20]. In our study, hypertension was more
prevalent within the older PCOS group even when adjusted
for BMI.
It has been shown that women with PCOS are frequently
developing centripetal obesity [21]. Particularly, the abdom-
inal phenotype of obesity is a clinical predictor of metabolic
abnormalities that can be detected in the early stages of PCOS
and could even precede its development [3]. Our results
showed that women with PCOS from the fourth decade
of life are more prone to develop centripetal obesity thus
representing a possible starting point for the development of
other metabolic disorders. This observation is in line with
the obtained significant positive correlations between WHR
and reliable clinical markers of CVD (TG/HDL ratio, SBP,
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and DBP) in our PCOS women. The above obtained asso-
ciations indicate the complex causative relationship between
abdominal obesity, the consequent development of insulin
resistance, and evenmore type 2 diabetes (T2D) that seems to
be intrinsic to PCOS and their BMI increase [22, 23]. Obesity
and insulin resistance predispose PCOS women to blood
pressure dysregulation, thus making obesity a major link
between PCOS and hypertension [24]. Moreover, hyperten-
sion was more prevalent within our PCOS women from the
fourth decade of life in comparison to both age-comparable
controls and younger PCOS, even after adjustment for BMI.
However, we did not confirmaggravation of insulin resistance
in PCOS in comparison to controls, although both groups
weremarkedly insulin resistant. A possible explanation could
lie in themethod used for the evaluation of insulin resistance,
thus lacking the precision to detect a difference [25].
The total cholesterol/HDL-cholesterol ratio was proved to
be a relevant parameter for the assessment of the increased
risk for CHD [16]. Although there was no age-related differ-
ence in this lipid index between our PCOS women and the
controls, the prevalence of the TC/HDL-C ratio ≥4 was
higher in older PCOS in comparison to both age-comparable
controls and younger PCOS. As TC/HDL-C ratio ≥4 is inde-
pendently associated with an increased prevalence of sig-
nificant obstructive coronary artery disease [16], our results
implicate higher CVR in PCOS with aging. Although we
found a significant correlation between the TC/HDL-C ratio
and both SBP and DBP, this index was not proved to be a
relevant predictor of hypertension in our PCOS population.
The TG/HDL-C ratio represents a reliable indirect indicator
of the size of the LDLparticles [26] andwas proved to be good
indicator for identifying subjects with insulin resistance and
a risk for the development of T2D and CVD in presumably
healthy individuals [27]. Our PCOS women older than 30
years had a significantly higher TG/HDL-C ratio than the
controls. Moreover, this lipid index was confirmed as an
independent predictor of both SBP and DBP in PCOS in
the fourth decade of life with a high diagnostic accuracy
for the diagnosing of hypertension in the whole PCOS
group irrespective of age. It could be speculated that the
proatherogenic potential could be translated even from the
adolescent period [26] to the fourth and later decades of life,
as the TG/HDL ratio reached a critical value in our PCOS
women older than 30 years.
We need to emphasize that in defining hypertension we
used the cut-off for SBP ≥130mmHg and DBP ≥85mmHg.
These values are present in all the current criteria for the
MetS that was shown to be prevalent in women with PCOS
[28]. In comparison to other studies, our TG/HDL-C ratio
cut-off value (1.10) for the prediction of hypertension in
PCOS was slightly lower than that previously proposed as
the most reliable in the discrimination of the atherogenic
LDL phenotype and the identification of women with an
accentuated cardiometabolic risk and T2D (1.33 and 2.0,
resp.) [17, 26]. The difference in our cut-off value could be
explained by the younger age of our study population. The
proposed TG/HDL-C cut-off could be an early identification
for PCOS with a risk of hypertension and first clinical
indicator for clinicians to pursue more on the prevention
strategies.
The effect of androgens on the blood pressure in women
with PCOS is still a controversial issue. It is assumed that
60–80% of PCOS women have hyperandrogenemia [29] and
that the cardiometabolic risk is prevalent in hyperandrogenic
PCOS phenotypes [30]. Several studies have shown that a
decreased SHBG and the consequent higher free testosterone
positively correlated with triglycerides and insulin levels and
negatively with HDL-C in both premenopausal women with
PCOS and those after menopause [31, 32]. In our study,
women with PCOS and the most pronounced hyperandro-
genemia, mirrored through the FAI, had significantly higher
proatherogenic lipid indexes as TG/HDL and TC/HDL,
thus implicating the role of androgens in such metabolic
derangements. These results were maintained after adjust-
ment for the BMI of the investigated PCOS women. It was
proposed that androgens increase the arterial blood pressure
in women with PCOS by altering the components of the
renin-angiotensin system. Namely, an increased expression
of renin and angiotensin in the granulosa and theca cells
in women with PCOS has been immunohistochemically
proven [33]. On the other hand, it was presumed that
androgen excess favours abdominal adiposity from an early
age and consequently facilitates insulin resistance [34]. The
existence of an aberrant morphology and function of adipose
tissue in women with PCOS is associated with hypoxia-
induced pathways leading to low-grade inflammation and the
consequent production of cytokines and chemokines, as well
as decreased production of adiponectin. A chronic low-grade
inflammatory state has been associated with the development
of local and systemic insulin resistance and, probably through
this mechanism, with T2D and CVR factors [35]. It is
suggested that androgens could represent mediators to these
processes by stimulating the differentiation of preadipocytes
into mature adipocytes and influencing the biochemical
pathways of lipid and carbohydrate metabolism, as well as
oxidative stress [36].
Besides arterial blood pressure, CIMT represents a vas-
cular surrogate marker with the potential for the prediction
of CVD in women with PCOS. It was suggested that an
increased CIMT is prevalent in young women with PCOS
[37]. However, some investigations either did not confirm
any differences in CIMT in younger PCOS women [38, 39]
or reported higher CIMT only in PCOS women over the
age of 45 in comparison to the controls [38]. Our results
are in line with this observation. Even more, our group
of women is among the largest investigated populations of
PCOS, thus giving more relevance to the lack of difference in
CIMT between PCOS women and controls and an absence
of any causative relation to other investigated CVR factors.
Hence, it could be supposed that not every CVR in young
women with PCOS is translated into the CVD or it is not yet
apparent at this early stage of the condition [39].Whether the
cardiovascular risk translates into increased cardiovascular
morbidity and mortality has not yet been fully elucidated as
appropriate long-term prospective studies are lacking.
CVD risk assessment in women with PCOS is rec-
ommended at any age for blood pressure, glucose, lipid
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profile (cholesterol, triglycerides, HDL, LDL, and non-HDL
cholesterol), waist circumference, physical activity, nutrition,
and smoking. Moreover, periodic reassessment for CVD risk
is recommended as CVD risk increases with age [40]. It is
recognized that the prevention of future adverse cardiovas-
cular effects is needed in women with PCOS. The primary
prevention of CVD involves lifestyle modification including
weight reduction using a low saturated fat diet and an indi-
vidualized exercise program. This is recommended as first-
line therapy for all women with PCOS and particularly for
those with serum LDL-C levels >160mg/dL (>4.14mmol/L)
and/or non-HDL-C levels >190mg/dL (>4.92mmol/L) when
additional therapy with cholesterol-lowering drug therapy
(statins) should be considered [41]. Recent meta-analysis of
the randomized clinical trials with simvastatin (20mg/day)
and atorvastatin (20–40mg/day) in women with PCOS
showed their effectiveness at reducing LDL-C, total choles-
terol, triglycerides, and testosterone levels [42]. At the initia-
tion of drug therapy, monitoring of lipid levels should follow
after 6 weeks [41].
5. Conclusion
Weobserved that womenwith PCOS possess the potential for
early atherosclerosis which can be detected through elevated
and deranged predictors of atherosclerosis, namely, lipids and
changes in blood pressure. It seems that the potential for
subclinical CVD becomes apparent from the fourth decade
of life, irrespective of their BMI. A more proper assessment
of the clinical phenotypes and use of specific metabolic
indicators could be a valuable tool for the evaluation of
cardiovascular potential and outcomes in future randomized
studies on women with PCOS.
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